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OBJECTIVE — To evaluate cardiovascular disease (CVD) and total mortality associated with
thoracoabdominal calciﬁcations.
RESEARCH DESIGN AND METHODS — Thoracoabdominal calciﬁcations of native
radiograms were evaluated in 833 subjects with type 2 diabetes and 1,292 subjects without
diabetes,aged45–64years,withoutpriorevidenceofCVD.Thetype2diabeticandnondiabetic
study cohorts were followed up for 18 years.
RESULTS — After adjustment for conventional risk factors, marked thoracoabdominal calci-
ﬁcations predicted CVD/total mortality with hazard ratio (HR) (95% CI) of 1.5 (0.8–3.0)/1.8
(1.1–2.9) in type 2 diabetic men, 3.0 (1.6–5.7)/3.1 (1.9–5.0) in type 2 diabetic women, 5.0
(2.2–12)/4.0 (2.2–7.4) in nondiabetic men, and 7.8 (1.8–34)/3.0 (1.3–7.0) in nondiabetic
womenandinthepresenceofC-reactiveproteinbelow/over3mg/lwithHRof2.4(1.3–4.4)/3.0
(1.4–6.1) in type 2 diabetic subjects and 4.0 (1.5–10.8)/6.6 (2.7–16.0) in nondiabetic subjects.
CONCLUSIONS — Thoracoabdominal calciﬁcations in native radiograms are signiﬁcant
predictors of CVD and total mortality, especially in type 2 diabetic and nondiabetic women with
elevated high-sensitivity C-reactive protein level.
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V
ascular calciﬁcation is initiated by
metabolic, mechanical, infectious,
or inﬂammatory injury to vascula-
ture.Itsprogressionismainlydetermined
by inﬂammatory response to vascular in-
jury (1). It may precede cardiovascular
disease(CVD)morbidityandmortalityby
years or decades in subjects with type 2
diabetes(2)andinthegeneralpopulation
(3–6). Medial calciﬁcation has been asso-
ciated with CVD morbidity and mortality
in diabetic subjects (7) and in subjects
with end-stage renal disease (8). Calciﬁ-
cations can be divided into intimal type,
medial type of arterial calciﬁcation, car-
diac valve calciﬁcation, and vascular cal-
ciphylaxis (9). These four entities of
calciﬁcationsareconsequencesofdistinct
but overlapping pathophysiological
mechanisms, which can occur simulta-
neously. Calciﬁcations may function as a
limiting factor for intimal plaque growth
andrepresentabiologicalresponsetothis
process (10). A new perspective to the
question of clinical signiﬁcance of calciﬁ-
cationhasevolvedfromthepracticalneed
to evaluate CVD effects of medications
targeted to bone formation and the bone
density effects of medications targeted to
vascular welfare (11,12).
Although inﬂammation is involved in
the initiation and progression of vascular
calciﬁcation, inﬂammation and calciﬁca-
tion may reﬂect partly independent pro-
cesses. A combination of markers of
calciﬁcation and inﬂammation might
therefore be a good predictor CVD mor-
tality. This study evaluates thoracoab-
dominal calciﬁcations, and their
combination with elevated high-sensitivity
C-reactive protein (hs-CRP), in prediction
of CVD mortality in a cohort of two dia-
betic and nondiabetic subjects without
prior evidence of CVD during an 18-year
follow-up.
RESEARCH DESIGN AND
METHODS— A detailed description
oftheoriginalstudypopulationincluding
1,059 type 2 diabetic and 1,373 nondia-
betic subjects aged 45–64 years has been
published previously (13). Subjects with
prior CVD (n  301) or missing informa-
tion on calciﬁcation (n  6) were ex-
cluded. Of 2,125 participants, 1,862
subjects (317 men and 370 women with
type 2 diabetes, 511 nondiabetic men,
and 610 nondiabetic women) were avail-
ablefortheanalysesofhs-CRP.Endpoints
were total and CVD mortality by the Inter-
nationalClassiﬁcationofDiseases,NinthRevi-
sion (ICD-9) codes 390–459. The 18-year
follow-up lasted until 1 January 2001.
hs-CRP was analyzed with latex tur-
bidimetric immunoassay (Wako Chemi-
cals, Neuss, Germany), with detection
limit of 0.06 mg/l. The interassay coefﬁ-
cient of variation was 3.3 and 2.7% at
meanhs-CRPlevelsof1.52(n116)and
2.51 (n  168) mg/l, respectively. From
lateral lumbar radiograms, taken with the
patient in a standing position, thoracoab-
dominal calciﬁcation was graded by a radi-
ologist (M.S.) from no calciﬁcation (grade
0)tomarkedcalciﬁcation(grade3)blinded
to clinical data. The  coefﬁcient (SE) for
intraobserver variation was 0.87 (0.24).
Data analyses were conducted with
the SPSS 14.0.1 program (SPSS, Chicago,
IL). Cox models for CVD and total mor-
tality were adjusted for age, sex, status of
diabetes, area of residence, current smok-
ing, systolic blood pressure, total choles-
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ﬁltration rate, urinary protein (log), fast-
ing glucose (in nondiabetic subjects) or
glycated hemoglobin A1 (in type 2 dia-
betic subjects), and duration of diabetes
(in type 2 diabetic subjects). A P value
0.05 was considered statistically signif-
icant. The ethics committees of the Kuo-
pio University Hospital and the Turku
University Central Hospital approved the
study. All study participants gave in-
formed consent.
RESULTS— During the 18-year fol-
low-up, 817 all-cause deaths and 465
CVD deaths occurred. Baseline charac-
teristics are given in online appendix
Table A1 (available at http://care.
diabetesjournals.org/cgi/content/full/dc09-
1813/DC1). Thoracoabdominal calciﬁca-
tions were more frequent in men than
women (66.1 vs. 55.7%) and in type 2
diabetic than nondiabetic subjects (71.5
vs. 53.6%). The presence of thoracoab-
dominal calciﬁcations was associated
with the presence of hs-CRP 3 mg/l in
type 2 diabetic women (P  0.006), not
quite in nondiabetic women (P  0.069),
and not in nondiabetic men (P  0.739)
or in type 2 diabetic men (P  0.550).
In multivariate analysis, thoracoab-
dominal calciﬁcations predicted CVD
mortality independently of other risk fac-
tors in type 2 diabetic women, nondia-
betic men, and nondiabetic women but
not in type 2 diabetic men (online appen-
dix Table A2). CVD survival was mark-
edly dependent on the presence of
calciﬁcations and the status of diabetes at
baseline,aspresentedbysexinonlineap-
pendix Fig. A1. There was no interaction
between sex and thoracoabdominal calci-
ﬁcations (P  0.678) in prediction of
CVD mortality. However, an interaction
was observed between sex and hs-CRP in
association with thoracoabdominal calci-
ﬁcations (P  0.037 for the interaction
term of hs-CRP by sex).
The association of thoracoabdominal
calciﬁcation grade with CVD and total
mortality was consistent in subgroups
with hs-CRP 3 and 3 mg/l (online ap-
pendix Fig. A2). Multivariate Cox analy-
sis, including both hs-CRP and
thoracoabdominal calciﬁcations, sug-
gested that they are independent predic-
tors of CVD and total mortality. Hazard
ratio (HR) of CVD death for calciﬁcation
tended to be higher in the presence of
elevatedhs-CRPthroughcalciﬁcationcat-
egories from 0 to 3 (Fig. 1).
CONCLUSIONS— In this 18-year
follow-upstudy,markedthoracoabdomi-
nal calciﬁcations predicted CVD and total
mortality, especially in nondiabetic and
type 2 diabetic women with elevated hs-
CRP level.
The relative risk associated with cal-
ciﬁcations was higher in nondiabetic sub-
jectscomparedwithdiabeticsubjectsand
in women compared with men. Predom-
inanceofaorticcalciﬁcationwasobserved
in women in the Reykjavik study, but sex
differences in the risk associated to calci-
ﬁcations have not been observed (14). In
our study, marked calciﬁcations tended
to signify a higher relative risk for CVD
mortality in women than in men, but a
statistically signiﬁcant interaction with
sex was not observed.
The risk increase of CVD death asso-
ciated with the presence of calciﬁcations
was lower in the presence of low hs-CRP
and higher in the presence of elevated hs-
CRP. Calcium deposits may alter or stim-
ulate the process of CVD (1), as they
accumulate in dying cells and lipoprotein
deposits, and activate endochondral and
intramembranous types of ossiﬁcation by
secretion of inﬂammatory cytokines, tu-
mor necrosis factor-, and interleukin-1
and interleukin-8 (15). In this study, an
interaction with sex between inﬂamma-
tory activity and grade of calciﬁcations
was observed.
Combininghs-CRP,asurrogateofac-
tivity of atherosclerosis with the presence
of calciﬁcations, a surrogate of stage of
atherosclerosis, the prognostic value im-
Figure 1—HR (95% CI) in Cox multivariate model of CVD mortality during 18-year follow-up
for grade 1 (slight), grade 2 (moderate), and grade 3 (marked) calciﬁcation of thoracoabdominal
aorta.ThereferencewithHR1arethesubjectswithnothoracoabdominalcalciﬁcations(grade0)
and hs-CRP 3 mg/l. Squares mark subjects with hs-CRP 3 mg/l and triangles mark subjects
withhs-CRP3mg/l.Inmultivariateanalysis,markedthoracoabdominalcalciﬁcationspredicted
CVD in the presence of hs-CRP below/over 3 mg/l with HR (95% CI) of 2.4 (1.3–4.4)/3.0 (1.4–
6.1) in type 2 diabetic subjects and 4.0 (1.5–10.8)/6.6 (2.7–16.0) in nondiabetic subjects.
Calciﬁcations predict cardiovascular mortality
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present study, detection of thoracoab-
dominal radiological calciﬁcation should
lead to a detailed evaluation and treat-
ment of CVD risk.
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